59 results about "Vascular Calcifications" patented technology

The present application is applicable to the field of medical technology, and provides a pharmaceutical composition for preventing and treating diabetic vascular calcification and a preparation method thereof, wherein the pharmaceutical composition comprises the following raw materials by mass: 15-25 parts of salvia miltiorrhiza, 9-12 parts of coptis chinensis, 9-12 parts of knotweed, 9-15 parts of rhodiola rosea and 9-12 parts of ebony. The present application uses a pharmaceutical composition prepared by compounding salvia miltiorrhiza, coptis chinensis, knotweed, rhodiola rosea and ebony in proportion, which can prevent and treat diabetic vascular calcification; in addition, it can also effectively improve blood sugar metabolism, and has the function of reducing aortic calcium salt deposition and improving aortic pathological morphology.

The invention discloses application of decitabine in preparation of a medicine for resisting vascular calcification, and belongs to the technical field of medical biology. A CKD mouse vascular calcification model is constructed through combination of 5 / 6 nephrectomy and high phosphorus diet (5 / 6NX), and it is observed that the expression level of DNMT3A in model mouse calcified blood vessels is remarkably increased, and the DNA methylation degree is remarkably increased. Based on this, people try to use decitabine to reduce the expression of DNMT, and discover that intraperitoneal injection of decitabine inhibits the expression of DNMT3A in CKD artery blood vessels and osteogenesis-like transdifferentiation of vascular smooth muscle cells, so that CKD-related vascular calcification is effectively relieved.

The invention discloses an application of an RUNX2 inhibitor in preparation of a medicine for treating vascular calcification related diseases, and the RUNX2 inhibitor comprises an ester compound which is selected from at least one of Corilagin, 1, 2, 3, 6-tetragalloylglucose, NADP (Nicotinamide Adenine Dinucleotide Phosphate), Stafib-2 and uridine triphosphate sodium salt. The ester compound provided by the invention is used as a drug for inhibiting vascular calcification and progression of the RUNX2 inhibitor, and provides a new thought, a target spot and a small molecule drug for treatment of vascular calcification. The five small molecule compounds have good drug safety and a strong vascular calcification inhibition effect, and can be used as candidate drugs for inhibiting vascular calcification.

A catheter system (100) for treating a treatment site (106) within or adjacent to a blood vessel (108) includes a power source (124), a light guide (122) and a plasma target (242). In various embodiments, the light guide (122) receives power from the power source (124). The light guide (122) has a distal tip (244), and the light guide (122) emits light energy (243) in a direction away from the distal tip (244). The plasma target (242) is spaced apart from the distal tip (244) of the light guide (122) by a target gap distance (245). The plasma target (242) is configured to receive light energy (243) from the light guide (122) so that a plasma bubble (234) is generated at the plasma target (242). The power source (124) can be a laser and the light guide (122) can be an optical fiber. The catheter system (100) can also an inflatable balloon (104) that encircles the distal tip (244) of the light guide (122). The plasma target (242) can be positioned within the inflatable balloon (104). The plasma target (242) can have a target face (1672) that receives the light energy (243) from the light guide (122). The plasma target (242) can be formed from one or more of tungsten, tantalum, platinum, molybdenum, niobium, iridium, magnesium oxide, beryllium oxide, tungsten carbide, titanium nitride, titanium carbonitride and titanium carbide.

The invention belongs to the field of biological medicine, and particularly relates to application of deaminotyrosine in preparation of a medicine for treating vascular calcification symptoms. The invention finds that deaminotyrosine can significantly reduce the vascular calcification degree of an in-vitro cell model and an in-vivo animal model by inhibiting osteogenic differentiation and calcium salt deposition of vascular smooth muscle cells; therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salt, ester, solvate or prodrug thereof in preparation of drugs for treating vascular calcification symptoms. The invention also provides a pharmaceutical composition, which takes deaminated tyrosine as an active component, and provides a brand new drug choice for clinical prevention and treatment of vascular calcification.

The utility model provides an adjustable bend ultrasonic recanalization catheter and an ultrasonic recanalization catheter system, the adjustable bend ultrasonic recanalization catheter comprises a catheter body, a metal cap and a handle, the metal cap is connected with the far end of the catheter body, and the handle is connected with the near end of the catheter body; an ultrasonic transmission part and at least one traction wire are arranged in the tube body in a penetrating manner, the near end of the ultrasonic transmission part penetrates out of the near end of the handle to be connected with ultrasonic equipment, and the far end of the ultrasonic transmission part is connected with the metal cap so as to be used for transmitting ultrasonic mechanical energy generated by the ultrasonic equipment to the metal cap; the handle comprises a handle body and a bending adjusting mechanism arranged on the handle body, the near end of the traction wire is connected with the bending adjusting mechanism, the far end of the traction wire is connected with the metal cap, and the bending adjusting mechanism is used for pulling the traction wire so that the tube body can be bent in at least one direction. According to the utility model, bending adjustment of the tube body can be realized, so that ultrasonic vibration treatment can be carried out on vascular calcification lesion positions with extremely tortuous, narrow or multi-branch structures, and the purpose of opening blood vessels is realized.

The invention provides application of retinoic acid in preparation of a medicine for treating vascular calcification, and belongs to the technical field of medicines. The early warning and treatment effects of retinoic acid on vascular calcification are provided for the first time, a new source is provided for preparing the medicine for early warning and / or treating vascular calcification, and meanwhile the new medicinal value of retinoic acid is explored. Cardiovascular calcification and vascular smooth muscle cell calcification are relieved by supplementing retinoic acid in vivo and in vitro, and the feasibility that retinoic acid can be used as a potential medicine for treating vascular calcification is prompted. The retinoic acid content is in negative correlation with the coronary artery calcification integral of the human body and the calcification severity degree, and it is prompted that the retinoic acid content can serve as an early warning index of cardiovascular calcification and the severity degree.

The invention discloses a vascular calcification dynamic monitoring method based on signal pattern recognition, and relates to the technical field of vascular mechanics signal analysis, and the method comprises the steps: obtaining acoustic original data of a target vascular region in a cardiac cycle, completing time synchronization and noise suppression based on a cardiac cycle starting point, and obtaining an acoustic data segment; constructing a displacement sequence changing along with time in the radial depth direction, and extracting amplitude, phase and deformation tracks to form a motion parameter set; arranging the motion parameters according to depths to construct a cardiac cycle response fingerprint matrix, and determining boundary positions of an intima, a middle membrane and an adventitia of a blood vessel wall according to motion mode differences of different depths; local offset features are collected and recognized based on multiple moments, the depth position of calcification in the blood vessel wall is determined, and dynamic monitoring of calcification along with time is achieved. According to the method, continuous presentation of the hierarchical structure of the blood vessel wall and fine expression of mechanical response of multiple layers of tissues are realized, and abnormal changes related to calcification can be sensitively recognized.

The application provides application of PCN in preparation of a drug for preventing and treating vascular calcification, belongs to the technical field of biological medicine, and further provides a drug for preventing or treating vascular calcification, wherein an effective component of the drug comprises PCN.The application applies PCN to treatment of vascular sclerosis, and can effectively improve vascular calcification and inhibit the development process of vascular calcification.

The invention discloses application of icariin in preparation of drugs for preventing and treating chronic kidney disease mineral substances and bone metabolism disorders. Relates to the technical field of medicine. The invention provides an application of icariin as an active pharmaceutical ingredient in preparation of a CKD-MBD treatment drug. Pharmacological experiments show that icariin can improve renal fibrosis, inhibit hyperparathyroidism, correct calcium and phosphorus metabolism, regulate and control bone metabolism related molecular expression, inhibit transdifferentiation of vascular smooth muscle cells to bone cells, inhibit vascular calcification and correct bone metabolism disorder, so that CKD-MBD is effectively prevented and treated. When icariin is used for preventing or treating CKD-MBD, the icariin is clear in component, exact in curative effect and low in side effect, and has a wide medical application prospect.

A catheter assembly of a shock-wave balloon catheter system, and a shock-wave generation system. The catheter assembly comprises: an outer tube; an inner tube, which is arranged in and runs through the outer tube, and forms a contraction portion at the distal end thereof; a balloon, which is sleeved outside the contraction portion, and has one end connected to the outer tube and the other end connected to the inner tube; and an electrode assembly, which is arranged between the contraction portion and the balloon. In the embodiments of the present application, the inner tube is provided with the contraction portion for accommodating the balloon, which can reduce the outer diameter of the balloon in a fully contracted state and in turn improve the capability of the catheter assembly passing through a blood vessel with vascular calcification and stenosis.

The present invention relates to a composition for preventing, ameliorating, or treating vascular calcification and a vascular disease associated therewith, which includes a Cdon-Ig2 domain or a peptide derived therefrom, and a method of providing information on the diagnosis of a disease associated with vascular calcification through the confirmation of the expression level of the peptide.

The invention relates to application of harmine in preparation of a medicine for preventing and treating vascular calcification. The harmine can be used for preventing and / or treating vascular calcification. Experiments show that harmine reduces osteogenic differentiation of vascular smooth muscle cells by down-regulating expression of RUNX2 and BMP2 and up-regulating expression of alpha-SMA at the same time, calcium salt deposition of blood vessels can be reduced, and it is indicated that harmine has a remarkable inhibition effect on vascular calcification. The new application of harmine in the anti-vascular calcification aspect is confirmed, so that the research of harmine in the technical field of medicines can be expanded, a new way is provided for research and development of drugs for treating vascular calcification, and a new theoretical direction is provided for clinical application.

The application relates to application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, and belongs to the technical field of biological medicine. In order to solve the problem that effective clinical means for treating vascular calcification is lacked at present, the application provides application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, the transcription or translation of the ACLY gene of vascular smooth muscle cells is efficiently and specifically inhibited, or the expression or activity of the ACLY protein of the vascular smooth muscle cells is efficiently and specifically reduced, the osteogenic differentiation of smooth muscle is reduced, the deposition of hydroxyapatite in the vascular media is reduced, and the progress of vascular calcification is alleviated. The medicine for preventing and treating vascular calcification is prepared on the basis of inhibition of the ACLY of vascular smooth muscle, has important clinical application potential for vascular calcification treatment, and can provide a new treatment option for patients with vascular calcification.

The present invention relates to the field of biopharmaceuticals. Specifically, the present invention provides an application of the miR21-5p / Tpm1 axis in the preparation of a medicament for preventing and / or treating diabetic vascular calcification. The present invention discovers for the first time the abnormal activation of the miR21-5p / Tpm1 axis in patients with diabetic vascular calcification, and further discovers a new mechanism in which miR21-5p negatively regulates Tpm1 to promote the osteogenic differentiation of vascular smooth muscle cells (VSMCs). Animal experiments prove that miR21-5p / Tpm1 inhibitors can effectively inhibit the occurrence and development of diabetic vascular calcification, providing a new idea and treatment plan for the clinical treatment of diabetic vascular calcification.

The invention provides application of a CXC chemokine ligand 13 as a vascular calcification diagnosis marker, and belongs to the technical field of medicines. The high expression of the CXCL13 prompts the high risk of vascular calcification, and the reagent for detecting the expression level of the CXC chemotactic factor ligand 13 can be used for preparing a vascular calcification early-warning reagent or early-warning kit. The invention studies the effect and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating and controlling vascular calcification, provides an early intervention target for vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of LGR5 in diagnosis and treatment of vascular calcification. Experiments prove that the key effect of the LGR5 in aortic smooth muscle calcification is found for the first time, it is indicated that the LGR5 is a new target spot for regulating and controlling vascular calcification, meanwhile, vascular calcification can be accurately inhibited through knockdown / knockout of the specific Lgr5 gene of vascular smooth muscle, and meanwhile, vascular calcification can be accurately inhibited through knockout / knockout of the specific Lgr5 gene of the vascular smooth muscle. According to the application disclosed by the invention, the mechanism that the Lgr5 regulates and controls the osteogenic differentiation of the vascular smooth muscle cells through the Wnt / beta-catenin signal channel is preliminarily clarified, and a clear action target and a theoretical basis are provided for drug research and development; the invention provides a new strategy for treatment of diseases such as atherosclerosis and the like, and has a wide clinical application prospect.

The present invention relates to a composition for improving cardiovascular calcification using a mulberry tree extract and a method for preparing the same. The composition is prepared by collecting the fruit (mulberry), leaves (mulberry leaves), branches (mulberry branches), and root bark (mulberry bark) of the mulberry tree, extracting the fruit and freeze-drying it to produce a mulberry extract, hot-air drying the leaves, branches, and root bark, adding 20-70% ethanol corresponding to 5-50% by weight of each, extracting at 50-90°C for 2-10 hours, filtering and concentrating the extract, and freeze-drying the extract to obtain a mulberry tree extract, and dissolving each extract in distilled water at a concentration of 10-50 mg / ml to provide a composition for improving cardiovascular calcification using a mulberry tree extract and a method for preparing the same, thereby enabling relatively safe and effective improvement of cardiovascular calcification, including vascular calcification.

The application discloses a calcification elimination system for vascular calcification lesions, and relates to the technical field of medical calcification elimination devices, which comprises a multi-cavity catheter, an ultrasonic conducting wire and a filter screen. A broken balloon is arranged on the outer wall of the multi-cavity catheter. The multi-cavity catheter comprises a suction cavity, a first filling cavity, a conducting wire cavity and a wire-retracting cavity, which all extend along the length direction. A suction hole is arranged on the distal end side wall of the suction cavity. The ultrasonic conducting wire is partially arranged in the conducting wire cavity. The proximal end of the ultrasonic conducting wire is connected with an ultrasonic energy source. The ultrasonic conducting wire has a spiral section, which is sleeved on the outside of the broken balloon. The filter screen is located on the distal end side of the broken balloon. The filter screen is connected with the distal end wall of the suction cavity. The outer edge of the filter screen is connected with a wire-retracting wire. The proximal end of the wire-retracting wire extends to the proximal end of the multi-cavity catheter through the wire-retracting cavity. The application can completely break the plaque, ensures complete breaking of the plaque and improves the breaking efficiency. In addition, the application avoids the problem of vascular thermal damage caused by the local concentration of ultrasonic energy.

The invention relates to an interventional catheter system for vascular calcification treatment, which comprises an imaging positioning module, an interventional catheter, a local sealing unit, a therapeutic agent release unit and a control unit, and is characterized in that the system identifies and positions a vascular calcification focus in real time through the imaging module, and navigates the interventional catheter to the focus under the guidance of an image; a treatment cavity for temporarily blocking blood flow is formed through expansion of the local sealing unit, a treatment agent is accurately released in the cavity through the treatment agent release unit, and the control unit coordinates navigation, sealing and release operation of the whole process. A local static and visual precise treatment environment is constructed for calcification lesions in a continuous blood flow environment for the first time, and high-concentration enrichment and retention of a therapeutic agent at the lesions are achieved, so that the decalcification curative effect is remarkably improved, meanwhile, the drug action range is strictly limited, systemic exposure, hypocalcemia and other side effects are effectively avoided, and the treatment effect is good. And the treatment safety is greatly improved.

The invention relates to the technical field of medical instruments, and provides an intravascular shock wave treatment system which comprises a host, a control handle arranged on the left side of the host, a shock wave balloon device arranged on the left side of the control handle and a catheter fixedly communicated between the control handle and the shock wave balloon device. A support is arranged outside the shock wave balloon device, and a reciprocating inflating device extending into the control handle is arranged in the control handle. The shock wave balloon device comprises a balloon, an impact device and a shock wave source device, and the support is connected to the outer surface of the balloon in a sleeving mode. The transmission mechanism is started to work through the host and the control handle, so that the pump body inflates the catheter and the balloon through the air inlet valve, the balloon expands and pushes the stent to expand the inner wall of a blood vessel, accurate control over the treatment process is achieved, periodic inflation and deflation of the balloon can be achieved, and the treatment efficiency of vascular calcification lesions is improved.

The present invention belongs to the field of Chinese medicine compositions, and in particular to a Chinese medicine composition for preventing and / or treating chronic kidney disease vascular calcification, and its preparation method and use. The Chinese medicine composition is a preparation prepared from the following raw materials in parts by weight: 5-15 parts of Radix Dichroae, 5-20 parts of Eucommia, 5-20 parts of Cistanche, 5-15 parts of Cuscuta, 5-20 parts of Rehmannia, 5-20 parts of Epimedium, 5-15 parts of Rhizoma Drynariae, 5-15 parts of Panax Japonicus, 5-20 parts of Millettia Spatholobi, and 5-20 parts of Semen Persicae. The Chinese medicine composition of the present invention can improve calcium-phosphorus metabolism disorder, protect the cardiovascular system, improve renal function, enhance cardiac function, inhibit vascular calcification, and prevent the transdifferentiation of vascular smooth muscle cells, with "tonifying the kidney, activating blood circulation and unblocking collaterals" as the treatment principle, by regulating the kidney-bone-vascular axis, inhibiting oxidative stress and inflammation, and intervening in calcium-phosphorus metabolism, thereby effectively treating CKD vascular calcification.

The present invention relates to the application of lipocalin 2 (LCN2) protein in the preparation of drugs for treating vascular calcification. The present invention respectively provides the application of LCN2 protein in the preparation of drugs for treating vascular calcification, a recombinant adeno-associated virus capable of increasing the expression level of LCN2 protein, and also provides a method for constructing the recombinant adeno-associated virus. Experiments have proved that the expression and secretion of LCN2 protein in vascular smooth muscle cells are inhibited under a high-phosphate environment. By administering exogenous LCN2 protein or transfecting VSMCs with a recombinant adeno-associated virus capable of highly expressing LCN2 protein, fatty acid β-oxidation can be promoted, thereby improving the situation of vascular calcification. Based on the experimental results, it can be known that LCN2 protein can play a role in treating vascular calcification, and therefore has good application prospects in the field of preparing related drugs.

The present invention relates to the technical field of tissue-engineered blood vessels, and specifically relates to an engineered exosome that can be applied to autologous blood vessels and small-caliber tissue-engineered blood vessels for anti-calcification, and a preparation method and application thereof. An engineered exosome has an E7 mesenchymal stem cell affinity peptide modified on its surface; and lncRNA-ANCR is encapsulated inside it. This engineered exosome can target Gli1+ cells in vivo and regulate their differentiation trend, and can reverse vascular calcification caused by chronic kidney disease; the small-caliber tissue-engineered blood vessels modified by it can accelerate the reconstruction of the smooth muscle layer of vascular grafts, have mechanical strength similar to that of natural blood vessels in vivo, and effectively inhibit the calcification of vascular grafts under normal and diabetic conditions by regulating the differentiation of smooth muscle progenitor cells. This solution can solve the technical problems of low efficiency of smooth muscle reconstruction in tissue-engineered blood vessels or autologous blood vessels and easy calcification of blood vessels, and at the same time meet the requirements of early cell reconstruction and long-term inhibition of calcification.

A method for identifying, quantifying, and phenotyping vascular calcification (VC) in patients includes accessing a set of medical scan images of a vascular tissue sample extracted from the one or more patients, and further inputting the set of medical scan images into one or more machine-learning models trained to segment the set of medical scan images to identify a tissue region, a lipid pool region, and a set of vascular calcifications detectable from the set of medical scan images. The method further includes determining, based on the segmented set of medical scan images, one or more feature characteristics corresponding to each of the identified set of vascular calcifications, and identifying each of the identified set of vascular calcifications as corresponding to one or more of a plurality of vascular calcification phenotypes based at least in part on the one or more feature characteristics and the identified lipid pool region.

The application discloses a kind of based on photoacoustic viscoelasticity imaging's diabetic foot microvessel calcification evaluation system and method, the method includes: pulsed laser of laser is emitted by focusing objective lens, is irradiated on the foot surface tissue of diabetic patient and generates photoacoustic signal;Using phase-locked amplifier extraction photoacoustic signal's phase delay;Computer control motor scans foot surface tissue and saves photoacoustic signal data and photoacoustic signal's phase delay data.Photoacoustic signal is processed to extract the time width information of wave crest, the wave crest time width data of each point photoacoustic signal and phase delay data are respectively mapped to image in the form of gray value, and the image about the elasticity and viscoelasticity of diabetic foot surface tissue is reconstructed.Calcification threshold and inflammation threshold are set, and the imaging area is divided into different elastic regions using threshold segmentation method, and then the vascular calcification of diabetic foot is evaluated using viscoelasticity parameters, to detect whether there is calcification and inflammation in the microvessel of diabetic foot.

The invention relates to application of a medicine taking an ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, and belongs to the technical field of biological medicines. In order to solve the problem that an effective clinical means for treating vascular calcification is lacked at the present stage, the invention provides application of a medicine taking an ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification. Or expression or activity of vascular smooth muscle cell ACLY protein is efficiently and specifically reduced, smooth muscle osteogenic differentiation is reduced, deposition of hydroxyapatite in blood vessel media is reduced, and the progress of vascular calcification is relieved. The medicine for preventing and treating vascular calcification is prepared on the basis of inhibiting vascular smooth muscle ACLY, has important clinical application potential in treatment of vascular calcification, and is expected to provide a new treatment choice for patients with vascular calcification.

The invention relates to application of an Nlrp3 gene and / or a knockout reagent thereof in construction of an arterial vascular calcification animal model. The construction method of the arterial vascular calcification animal model comprises the following steps: (1) constructing a gene editing system for targeted knockout of a mouse Nlrp3 gene; (2) performing gene editing on a mouse fertilized egg by using the gene editing system in the step (1), and inserting loxP sites at two ends of the Nlrp3 gene; and (3) carrying out mating propagation on the mouse obtained in the step (2) and a mouse expressing Cre recombinase to obtain a mouse of which the Nlrp3 gene is knocked out, and culturing to obtain the arterial vascular calcification animal model. The arterial vascular calcification mouse is obtained by specifically knocking out the Nlrp3 gene of the mouse, and the arterial vascular calcification mouse has important application value in the aspects of mechanism exploration of arterial vascular calcification diseases and drug research and development.

The invention provides application of PCN in preparation of a medicine for preventing and treating vascular calcification, belongs to the technical field of biological medicine, and further provides a medicine for preventing or treating vascular calcification, and the effective component of the medicine comprises PCN. According to the application, PCN is used for treating angiosclerosis, vascular calcification can be effectively improved, and the development process of vascular calcification is inhibited.

The invention discloses a multi-task joint segmentation method for kidney stone and vascular calcification in a coronary CTA image, and relates to the technical field of image segmentation processing, and the segmentation method comprises the following steps: obtaining coronary CTA image data, constructing a multi-task joint segmentation network, inputting the standardized image data into a shared feature encoder, and obtaining a shared feature encoder; and performing inter-task feature interaction enhancement on the multi-scale feature representation through a task interaction module to obtain enhanced feature representation, respectively inputting the enhanced feature representation into a kidney stone segmentation decoder and a vascular calcification segmentation decoder, and generating a final joint segmentation mask image according to a kidney stone segmentation result and a vascular calcification segmentation result. The method has the advantages that the segmentation of kidney stone and vascular calcification is completed in a single network at the same time through a multi-task joint learning framework, and compared with a scheme of independently training two models, the model complexity and computing resource consumption are reduced, and the feasibility of practical application is improved.